Gompertz pharmacokinetic model for drug disposition

Development of 41Ca-based pharmacokinetic model for the study of bone remodelling in humans

BACKGROUND AND OBJECTIVE

Initial studies show that 41Ca may be employed as a useful diagnostic bioassay for monitoring metabolic bone disease and its treatment management. The 41Ca-based pharmacokinetic model is developed to assess its feasibility in monitoring bone disease and clinical responsiveness to therapeutic regimens.

METHODS

A four-compartment calcium kinetic model is developed to interpret the results of clinically measured 41Ca tracer kinetics for oral and intravenous dose. This model is extended to simulate changes in bone turnover due to osteoporosis by using Gompertzian function with and without cellular accommodation. The rate constants obtained by fitting to the experimental data on drug intervention are used to simulate the impact of strategic treatment intervention.

RESULTS

The present model fits well with the available experimental data on 41Ca tracer kinetics. In the simulated osteoporotic model, the negative bone balance (i.e. bone loss) reflected by 41Ca/Ca urine ratio is used to demonstrate slow/fast increase over time compared to the normal state. The cellular accommodation impact is reflected by a recovery from perturbed balance. The model's predictive ability on the impact of therapeutic intervention is verified using published experimental data. The effect of bisphosphonate intervention results in positive bone balance (i.e. bone gain).

CONCLUSION

The four-compartment 41Ca tracer kinetic model can be flexibly used in the interpretation of results obtained from ongoing clinical studies.

Real-Time Observation for the Enzymatic Reaction of Phospholipid Membrane: Application of the Time-Resolved Quasi-Elastic Laser Scattering Method

An analytical technique to measure reactions in biological membranes was developed and applied to monitoring the hydrolysis reaction of phospholipids (dipalmitoylphosphatidylcholine, DPPC) by phospholipase A(2). The technique uses the time-resolved quasi-elastic laser scattering (TR-QELS) method to measure an oil/phospholipid monolayer/water membrane system by monitoring the change of interfacial tension under a noncontact condition and in real time. When the TR-QELS method is used with the newly developed oil/phospholipid monolayer/water membrane system, measurement of the hydrolysis reaction of phospholipids with long alkyl chains (C >or=16), which are the major components in biological membranes, becomes possible. The reaction progress is monitored by the increase of interfacial tension at the oil/water interface caused by the decrease of surface-active DPPC molecules due to the reaction. The characteristic phases, namely, lag, burst, and equilibrium, are observed. The relationship between the duration of the lag phase (the rate-limiting step of the reaction) and the concentration of calcium ion (an essential cofactor of the reaction) is also investigated. Increase of calcium ion concentration in the subphase is found to shorten the duration of the lag phase. In addition, the real-time measurement simplifies the estimation process for the reaction activation energy.

Direct, differential-equation-based in-vitro-in-vivo correlation (IVIVC) method

A new, differential equation-based in-vitro-in-vivo correlation (IVIVC) method is proposed that directly relates the time-profiles of in-vitro dissolution rates and in-vivo plasma concentrations by using one- or multi-compartment pharmacokinetic models and a corresponding system of differential equations. The rate of in-vivo input is connected to the rate of in-vitro dissolution through a general functional dependency that allows for time scaling and time shifting. A multiplying factor that accounts for the variability of absorption conditions as the drug moves along is also incorporated. Two data sets incorporating slow-, medium-, and fast-release formulations were used to test the applicability of the method, and predictive powers were assessed with a leave-one-formulation-out approach. All fitted parameters had realistic values, and good or acceptable fits and predictions were obtained as measured by plasma concentration mean squared errors and percent AUC errors. Introduction of step-down functions that account for the transit of the dosage form past the intestinal sites of absorption proved useful. By avoiding the integral transforms used in the existing deconvolution- or convolution-based IVIVC models, the present method can provide increased transparency, improved performance, and greater modelling flexibility.